Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak. (March 2021)

• Record Type: Journal Article
• Authors: Maciorowski, Dawid; Ogaugwu, Christian; Durvasula, Subba Rao; Durvasula, Ravi; Kunamneni, Adinarayana
• Is Part Of: SLAS discovery. Volume 26:Number 3(2021)
• Page Start: 311
• Page End: 329
• Publication Date: 2021-03
• Subjects: COVID-19 -- SARS-CoV-2 -- therapeutics -- vaccines -- drug repurposing; Drugs -- Analysis -- Periodicals; Drugs -- Testing -- Periodicals; Biomolecules -- Analysis -- Periodicals; Biomolecules -- Analysis; Drugs -- Analysis; Drugs -- Testing; Drug Evaluation, Preclinical; Molecular Biology -- methods; Periodicals; Periodicals; 615.1
• DOI: 10.1177/2472555220979579
• Languages: English
• ISSNs: 2472-5552

Abstract

An outbreak of the coronavirus disease 2019 (COVID-19) caused by an infection of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, China, in December 2019. This new virus belongs to the group of enveloped RNA beta-coronaviruses. Symptoms may differ in various infected persons, but major presentations include dry cough, nasal congestion, shortness of breath, fever, and general malaise. The disease appears to be more severe in patients above the age of 60 years and those with underlying conditions such as diabetes, cancer, cardiovascular diseases, chronic respiratory disease, and hypertension. There is still no approved vaccine against COVID-19, but more than a hundred are at different stages of development. It is known that the development of new drugs takes a relatively long time, so several known and already-approved drugs are being repurposed for the treatment of this disease. In this review, we explore the therapeutic and vaccine options that are available for COVID-19 6 months after its outbreak. Most noteworthy among the therapeutic options are dexamethasone, remdesivir, Avigan (favipiravir) and convalescent plasma.